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Abstract
Background: Endothelial dysfunction might contribute to the development of lepto-
spiral pulmonary hemorrhage syndrome (LPHS).
Hypothesis: Serum concentrations of markers of endothelial activation and dysfunc-
tion are higher in dogs with leptospirosis and correlate with the occurrence of LPHS
and a higher case fatality rate.
Animals: Clinically healthy dogs (n = 31; 10/31 dogs confirmed healthy based on no
detected abnormalities on blood work), dogs with leptospirosis with LPHS (n = 17)
and without LPHS (n = 15), dogs with acute kidney injury not due to leptospirosis
(AKI-nL, n = 34).
Methods: Observational study. Serum concentrations of soluble intercellular adhe-
sion molecule 1 (sICAM-1), vascular endothelial growth factor (VEGF), and
angiopoietin-2 (Ang-2) at admission were compared between groups. Correlations
with outcome and the accuracy to predict LPHS were examined.
Results: Soluble intercellular adhesion molecule (sICAM-1), VEGF, and Ang-2 concen-
trations were higher in dogs with AKI-nL (sICAM-1 34.7 ng/mL, interquartile range
[IQR] = 24.4-75.5; VEGF 43.1 pg/mL, IQR = 12.3-79.2; Ang-2 8.5 ng/mL,
IQR = 6.2-12.3), leptospirosis without LPHS (sICAM-1 45.1 ng/mL, IQR = 30.6-59.0;
VEGF 32.4 pg/mL, IQR = 12.5-62.6; Ang-2 9.6 ng/mL, IQR = 6.9-19.3), and LPHS
(sICAM-1 69.7 ng/mL, IQR = 42.1-89.1; VEGF 51.8 pg/mL, IQR = 26.3-96.7; Ang-2
8.0 ng/mL, IQR = 5.6-12.2) compared to controls (P < .001). In dogs with leptospiro-
sis, VEGF and sICAM-1 were higher in nonsurvivors (sICAM-1 89.4 ng/mL,
IQR = 76.5-101.0; VEGF 117.0 pg/mL, IQR = 90.3-232.4) than survivors (P = .004)
and sICAM-1 predicted the development of LPHS.
Abbreviations: AKI, acute kidney injury; AKI-nL, acute kidney injury not due to leptospirosis; Ang-2, angiopoietin-2; AUC, area under the curve; CRP, C-reactive protein; CV, coefficient of
variation; ICAM, intercellular adhesion molecule; IQR, interquartile range; LLD, lower limit of detection; LPHS, leptospiral pulmonary hemorrhage syndrome; MAT, microscopic agglutination test;
ROC, receiver-operating characteristics; sICAM, soluble intercellular adhesion molecule; VEGF, vascular endothelial growth factor.
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Conclusions: Soluble intercellular adhesion molecule 1, VEGF, and Ang-2 do not dis-
criminate leptospirosis from AKI-nL. In dogs with leptospirosis, sICAM-1 and VEGF
predict outcome and sICAM-1 might identify dogs at risk for LPHS.
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1 | INTRODUCTION
Leptospiral pulmonary hemorrhage syndrome (LPHS) is a severe form
of leptospirosis. It has been increasingly recognized in humans and
dogs and has become a major cause of death.1,2 The pathogenesis of
LPHS is poorly understood, hampering the application of effective
therapies. Leptospiral pulmonary hemorrhage syndrome is character-
ized by rapidly progressive intra-alveolar hemorrhage in the absence
of pulmonary inflammatory cell infiltration.3-5 In contrast to liver and
kidney, relatively few leptospires can be found in lung tissue of
affected humans and animals.3,5,6 While leptospirosis might lead to
both hyper- or hypocoagulable states, there is no clear association
between hypocoagulation and LPHS.5,7,8 Evidence has emerged
suggesting a role of the endothelium in many of the disease manifes-
tations of leptospirosis, including LPHS.9,10
Direct contact of endothelial cells with live Leptospira spp. or lep-
tospiral proteins in vitro leads to endothelial cell activation with over-
expression of ICAM-1 and E-selectin,11-13 loss of adherens junction
proteins,14 and loss of monolayer integrity.10 Furthermore, ICAM-1
and vascular cell adhesion molecule are overexpressed in lung tissue
from human patients with LPHS compared to patients with pulmonary
hemorrhage due to other causes, supporting the hypothesis that
endothelial activation plays a role in the pathogenesis of LPHS.6
While direct determination of the functional and structural state
of the endothelium is difficult in vivo, serum markers of endothelial
activation and dysfunction are well described in human patients
with leptospirosis. Serum concentrations of soluble ICAM-1,15,16
E-selectin,15,17 angiopoietin-2 (Ang-2),18 vascular endothelial growth
factor (VEGF),19 and syndecan-116 are increased in human patients
with leptospirosis compared to healthy controls, and increased serum
concentrations of sICAM-1,16 syndecan-1,16 VEGF,19 and Ang-218 are
associated with a more severe clinical course of disease as defined by
the presence of acute kidney injury (AKI), sepsis, and intensive care
admission. Soluble E-selectin serum concentrations are higher in non-
survivors, but E-selectin serum concentrations are not associated with
bleeding in this cohort.20 Increased concentration of endothelial acti-
vation markers could be caused by shedding of cell surface ICAM-1
by leptospiral proteases,15,21,22 endothelial activation, or endothelial
damage.16 However, a control group of patients with AKI of other eti-
ologies is not included in any human study, therefore precluding any
conclusions with regards to the specific pathogenic mechanism of lep-
tospirosis compared to other causes of AKI. Furthermore, their associ-
ation with the occurrence of pulmonary hemorrhage has not been
examined in detail.
The aims of this study were to explore serum markers of endo-
thelial activation (sICAM-1) and dysfunction (VEGF, Ang-2) in order to
better understand the role of the endothelium in the pathogenesis of
LPHS and to identify suitable biomarkers predicting the occurrence of
LPHS and outcome.
We hypothesized that serum concentrations of sICAM-1, VEGF,
and Ang-2 are increased in dogs with leptospirosis compared to
healthy dogs and dogs with AKI not due to leptospirosis (AKI-nL) and
that in dogs with leptospirosis, serum concentrations of these markers
are positively correlated with the occurrence of LPHS and a poorer
outcome.
2 | MATERIALS AND METHODS
2.1 | Study design
Dogs with leptospirosis with LPHS (LPHS group) and without LPHS
(Leptospirosis group) and dogs with AKI due to other causes (AKI-nL)
which were presented to the Vetsuisse Faculty Bern (Switzerland)
between 2013 and 2017 were included in this observational study.
Clinically healthy staff-owned dogs and healthy control dogs from a
genetic screening project were included as controls.23 Prospectively
collected samples (n = 17) from dogs with leptospirosis, LPHS and
AKI-nL as well as fresh aliquots of samples from the same cohorts col-
lected for previous studies (n = 49) were used. Owner consent for the
collection of blood samples from healthy dogs and the use of clinical
data and surplus samples from dogs was obtained before enrolment.
2.2 | Animals
All dogs in the control group were deemed clinically healthy based
on history and no detected abnormalities on physical examination.
CBC and biochemistry profile to support their good health and to
calculate correlations with endothelial cell activation or dysfunction
and markers of inflammation such as neutrophil and band neutrophil
counts and C-reactive protein (CRP) was performed in 10/31
control dogs.
All sick dogs underwent clinical evaluation including physical
examination, CBC, routine biochemistry, and urine analysis if they
were not anuric, and abdominal ultrasound. Further diagnostic testing
was directed by the specific problems of the dogs and included tho-
racic radiography, urine culture as well as testing for other potential
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infectious agents such as serologic testing against Angiostrongylus vas-
orum, Ehrlichia canis, Anaplasma phagocytophilum, or detection of
Babesia canis via blood PCR.
In dogs with AKI or a suspicion of leptospirosis, microagglutination
testing (MAT) was performed according to OIE standards at the national
reference laboratory for animal leptospirosis against a panel of patho-
genic Leptospira including serovars Grippotyphosa, Australis, Bratislava,
Canicola, Icterohemorrhagiae, Copenhageni, Pomona, Tarassovi, Hardjo,
Bataviae, Autumnalis, and Sejroe.24
2.3 | Case definitions
2.3.1 | Group 1: Acute leptospirosis without
pulmonary hemorrhage (Leptospirosis group)
A diagnosis of leptospirosis was based on clinical findings and the
presence of at least 1 of: a positive urine or tissue real time-PCR,25
MAT seroconversion with 4-fold rise in titer, a single positive MAT
titer of ≥1 : 800, a single positive IgM lateral flow assay (Witness
Lepto, Canine Leptospira Antibody Test Kit, Zoetis Deutschland
GmbH, Germany), or a strong clinical evidence with at least 2 classical
organ manifestations of leptospirosis (renal, hepatic, or hemorrhagic)
in the absence of another etiology. The last criteria was only consid-
ered in cases where leptospirosis could not be confirmed serologically
due to early death. Leptospiral pulmonary hemorrhage syndrome was
excluded by the absence of clinical signs and pulmonary infiltrates on
thoracic radiographs.
2.3.2 | Group 2: Acute leptospirosis with
pulmonary hemorrhage (LPHS group)
The diagnosis of acute leptospirosis was made as described for group
1. The diagnosis of LPHS was based on clinical signs and radiographic
evidence of multifocal alveolar infiltrates. This approach is limited by
the fact that alveolar patterns can also be caused by other pathologies
such as pneumonia or fluid overload. However, more aggressive diag-
nostics to confirm the presence of intra-alveolar bleeding such as
bronchoscopy and bronchoalveolar lavage were not performed
because of the anesthetic risk and the risks of respiratory complica-
tions due to the lavage procedure.
2.3.3 | Group 3: AKI-nL group
Dogs were included in this group if they presented with acute renal
azotemia and leptospirosis was excluded in this cohort based on the
absence of seroconversion on paired serum samples or a single recip-
rocal MAT titer of ≤1 : 200 in conjunction with a convincing alterna-
tive diagnosis. Acute kidney injury was diagnosed in the context of
consistent historical, clinical, or laboratory findings if at least 2 of the
following criteria were fulfilled: (a) presence of renal azotemia with a
serum creatinine concentration ≥ 1.7 mg/dL, persisting at least
24 hours after correction of prerenal factors; (b) increase in serum
creatinine ≥ 0.3 mg/dL during a 48 hours interval in the absence of
prerenal factors; (c) persistent pathological oligo/anuria (<1 mL/kg/
min over 6 hours) after volume repletion; and (d) evidence of tubular
injury with renal glucosuria or granular casts on urinalysis. Dogs with
evidence of underlying chronic kidney disease were not excluded
from the study.
2.3.4 | Group 4: Healthy dogs
This group contained clinically healthy dogs from a genetic study and
clinically healthy staff-owned dogs.23 Dogs in this group had no
abnormalities on history and physical examination. CBC and biochem-
istry panels, confirming the health of control dogs, were only available
for 10 of 31 animals.
2.4 | Sample collection and handling
Blood was collected from the Vena saphena lateralis, Vena cephalica, or
Vena jugularis using a 21 gauge needle into serum or lithium heparin
tubes (Microvette 200 uL; Sarstedt AG, Nümbrecht, Germany), or
both. Heparinized blood was centrifuged at 4000 rpm for 10 minutes
at 4C to separate plasma from cellular components. Plasma was used
for biochemical analysis. For collection of serum, blood was left to clot
for 30 minutes at room temperature. After centrifugation at ambient
temperature, serum was separated and frozen at 80C until further
analysis. No proteolytic inhibitors were added to the serum before
refrigeration.
Samples were collected between January 2016 and December
2017 on day 1 and, if possible, also on day 3 after admission. In
addition, serum samples stored at 80C from dogs with leptospiro-
sis with and without LPHS as well as AKI-nL and healthy dogs pres-
ented between January 2013 and December 2015 were used
Associations between storage time and the concentrations of
sICAM-1, Ang-2, and VEGF were examined via multiple linear
regression analysis (sICAM-1) or ordinale regression analysis (Ang-2,
VEGF) using disease group and sampling date as covariables and did
not show any association between serum concentrations and stor-
age time (data not shown).
2.5 | Sample analysis
For all ELISA assays, samples were measured in duplicate by the same
person and the measurements were repeated if the coefficient of vari-
ation (CV) between duplicates was >10%.
Serum sICAM-1 was measured using a commercial canine-specific
ELISA-kit (SEA548Ca; Cloud-Clone Corp., Houston, Texas) according
to the manufacturer's instructions. This ELISA-kit was previously used
for the measurement of canine soluble ICAM-1 in serum of dogs with
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babesiosis.26 Samples were diluted 1 : 3 in phosphate buffered saline
(PBS). Samples from 3 dogs were used to calculate interassay variabil-
ity and aliquots of these samples were measured on all plates. In our
experiments, the mean intra-assay variability was 4.2% and the lower
limit of detection (LLD) 1 ng/mL. As the interassay variability was very
high (CV = 57%), sICAM-1 concentrations were first compared
between groups for each plate (Table S1, Figure S1A-F) and subse-
quently across plates after normalization of the values via a correction
factor. The correction factor was calculated as the average sICAM-1
value of the 3 controls on the reference plate divided by the average
value of these controls on the test plate (Table S2). Plate 2 was taken
as reference as the measured values lay in-between those of plates
1 and 3. Selection of plate 1 or plate 3 as reference would have
resulted in different correction factors but would have equally allowed
to examine the relative differences between groups.
Serum VEGF concentrations were measured using a commercial
canine VEGF ELISA kit (Canine VEGF Quantikine ELISA Kit, R&D Sys-
tems, Inc, Minneapolis, Minnesota; product datasheet available at:
https://www.rndsystems.com/products/canine-vegf-quantikine-elisa-
kit_cave00) as previously described. This assay has been validated for
measurement of canine VEGF and was previously used by our group
to detect VEGF concentrations in dogs with systemic inflammatory
response syndrome or sepsis and in healthy dogs.27 Inter- and intra-
assay variability were assessed in a previous study in our laboratory
and were 4.6% and 4.9%, respectively.27 The LLD of the assay was
set at 15 pg/mL, which corresponds to the concentration of the low-
est standard.
Serum Ang-2 concentration was measured according to the manufac-
turer's instructions using a commercial ELISA test kit (Human
Angiopoietin-2 Immunoassay; R&D Systems, Inc; product datasheet avail-
able at: https://www.rnsystems.com/products/human-angiopoietin-2-
quantikine-elisa-kit_dang20) for use in humans that was validated for use
in dogs.28 Samples were diluted 1 : 5 with calibrator d iluent. If the mea-
sured Ang-2 concentration was outside the range of the standard curve
(standard curve: 0.05-3 ng/mL) samples were retested at a dilution of
1 : 10. If these samples were still above the detection limit at the 1 : 10 dilu-
tion, they were retested once more at a dilution of 1 : 20 in order to obtain
concentrations within the standard curve.
The respective coefficients of variation reflecting intra- and
interassay variability were assessed in a previous study in our laboratory
and were 5.6% for samples with high or low Ang-2 concentrations, and
6.7% (low concentrations) and 4.0% (high concentrations), respectively.28
2.6 | Statistical analysis
Statistical analysis was performed using a commercial software pack-
age (NCSS Statistical Software, 2016; NCSS; LLC, Kaysville, Utah,
available at: ncss.com/software/ncss). Descriptive statistics were per-
formed for dog characteristics, including sex, neuter status, age, body
weight, and baseline blood variables. Shapiro-Wilk testing indicated
non-normal distribution for several continuous variables, which were
therefore reported as median and interquartile range (IQR).
As 52% of VEGF measurements were below the lower level of
detection of 15 pg/mL, the frequency of VEGF concentrations below
the LLD was compared between disease groups and between survi-
vors and nonsurvivors among dogs with leptospirosis (Leptospirosis
and LPHS groups) using Fisher's exact test. Differences in serum con-
centrations of sICAM-1, VEGF, and Ang-2 and of markers of inflam-
mation, including neutrophil count, band neutrophils, albumin, and
CRP, were compared between disease groups and among dogs with
leptospirosis between survivors and nonsurvivors using the Kruskal-
Wallis Multiple Comparison Z-Value test (which corrects for multiple
comparisons). For this analysis, VEGF measurements below the LLD
were substituted with an LLD/2 (7.5 pg/mL).29
Outliers were generally not excluded from the analysis. Dogs
euthanized for financial reasons rather than intractable disease were
excluded from the outcome analysis.
Because of non-normal distribution of the data, the correlation
between sICAM-1, VEGF, and Ang-2 and the associations of these
3 markers with clinical and laboratory variables and outcome were
assessed using the Spearman rank correlation test.
The performance of sICAM-1, VEGF, and Ang-2 to discriminate
healthy from diseased dogs, dogs with leptospirosis from dogs with
AKI-nL and healthy dogs and dogs with LPHS from the other groups
and to predict a negative outcome was assessed using receiver-
operating characteristics (ROC) analysis. Optimal cutoff points for sensi-
tivity and specificity were determined using the most favorable cost-
benefit ratios to obtain the largest possible proportion of correctly clas-
sified dogs and were reported if the area under the curve (AUC) was
>0.5. Statistical significance for all statistical tests was set at P < .05.
3 | RESULTS
3.1 | Study sample
Samples and clinical data from 97 dogs were used for this study: 15 dogs
with leptospirosis without LPHS (Leptospirosis group), 17 dogs with LPHS
(LPHS group), 34 dogs were diagnosed with AKI due to other causes than
leptospirosis (AKI-nL group), and 31 dogs were clinically healthy. Twelve
dogs were crossbreeds and 85 were purebreds belonging to 38 different
breeds, the most common breeds being Labrador Retriever (n = 16), Mali-
nois (n = 15), Golden retriever (n = 5), Siberian Husky (n = 5), German
shepherd (n = 4), and Bernese Mountain dog (n = 4). Malinois dogs (14/
31; 45%) were overrepresented in the group of healthy dogs, as these
dogs were primarily recruited to participate as healthy controls in a genetic
survey.23 There were 54 males (entire n = 23; neutered n = 31) and 43
females (entire n = 8; spayed n = 35) included in the study. There were
no significant differences regarding age, body weight, sex, and neuter sta-
tus across the 4 groups. Characteristics of healthy dogs, dogs with AKI,
and dogs with leptospirosis with and without LPHS are shown in Table 1.
Of the 31 dogs included as healthy controls, 21 were deemed
healthy based on no abnormalities on history and physical examina-
tion and 10 had additional CBC and biochemistry panels performed
and no abnormalities were detected.
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In dogs with leptospirosis, the diagnosis was confirmed in
12 dogs via a single MAT of ≥1 : 800 and in 17 dogs by a ≥4-fold
rise in MAT titer in paired serum samples to 1 or several serovars.
Three dogs had a single positive rapid diagnostic test. Leptospirosis
was excluded in dogs with AKI-nL by a paired MAT titer (n = 9) or a
single titer below 1 : 800 (n = 11) and a convincing alternative diag-
nosis (n = 14). Of the 34 dogs with AKI, 10 had a history of inges-
tion of nephrotoxic substances (grapes n = 6; non-steroidal anti-
inflammatory drugs n = 2; ethylene glycol n = 1; maleic acid n = 1).
Acute on chronic kidney disease was present in 6 dogs, pyelonephri-
tis in 2, AKI following heat stroke in 2 dogs, and 1 each of the fol-
lowing: trauma, renal amyloidosis, glomerulonephritis, snake bite,
and hemolytic uremic syndrome. The origin of AKI remained
unknown in 9 dogs.
3.2 | Baseline laboratory variables
All 3 disease groups (AKI-nL, leptospirosis, LPHS) showed significant
differences in median thrombocyte count, urea, creatinine, bilirubin,
and albumin compared to healthy controls. Hematocrit was signifi-
cantly lower in the LPHS group compared to the AKI-nL and leptospi-
rosis groups. C-reactive protein was significantly lower in healthy
dogs and AKI-nL group compared to leptospirosis and LPHS groups
(Table 1). Among dogs with leptospirosis (with and without LPHS)
median bilirubin concentrations were significantly higher in non-
survivors compared to survivors (Table 2).
3.3 | Serum sICAM-1 concentrations
Comparison of day 1 serum sICAM-1 concentrations between groups
within ELISA plates showed consistently higher concentrations for
leptospirosis, LPHS, and AKI-nL groups compared to healthy controls
(Table S1, Figure S1). Median corrected day 1 sICAM-1
concentrations were significantly higher in dogs with AKI-nL (n = 16;
34.7 ng/mL; IQR, 24.4-75.5), leptospirosis (n = 9; 45.1 ng/mL; IQR,
30.6-59.0), and LPHS groups (n = 14; 69.7 ng/mL; IQR, 42.1-89.1)
compared to healthy controls (n = 31; 18.6 ng/mL; IQR, 9.9-23.6;
P < .001; Figure 1A). There were no significant differences between
the 3 disease groups. Median corrected serum sICAM-1 was signifi-
cantly higher in dogs with leptospirosis with or without LPHS which
died or were euthanized due to intractable disease (n = 4; 89.4 ng/
mL; IQR, 76.5-101.0) compared to dogs that survived to discharge
(n = 19; 50.9 ng/mL; IQR, 30.7-65.4; P = .004; Figure 2A).
Median day 3 corrected serum sICAM-1 in dogs with LPHS
(n = 5; 87.5 ng/mL; IQR, 52.3-101.7) was 3 times that of dogs with
AKI-nL (n = 5; 32.3 ng/mL; IQR, 10.9-80.3) or leptospirosis without
LPHS (n = 2; 31.6 ng/mL; IQR, 29.3-34.0), but the numbers of avail-
able samples were small and this difference not statistically signifi-
cant (P = .16).
3.4 | Serum VEGF concentrations
Serum day 1 VEGF concentrations were below the LLD (15 pg/mL) in
96% (n = 30/31) of healthy dogs, 27% (n = 3/18) of dogs with AKI-
nL, 25% (n = 2/8) of dogs with leptospirosis without LPHS, and 14%
(n = 2/14) of dogs with LPHS. The frequency of day 1 VEGF concen-
trations below the LLD was significantly higher in healthy dogs
(P < .001) compared to the 3 disease groups but was not significantly
different between the 3 disease groups.
Median serum day 1 VEGF was significantly higher in dogs with
AKI-nL (n = 18; 43.1 pg/mL; IQR, 12.3-79.2), leptospirosis (n = 8;
32.4 pg/mL; IQR, 12.5-62.6), and LPHS groups (n = 14; 51.8 pg/mL;
IQR, 26.3-96.7) compared to healthy controls (P < .001; Figure 1B).
There was no significant difference between disease groups.
Median day 1 VEGF was significantly higher in dogs with lepto-
spirosis with or without LPHS, which died or were euthanized due to
intractable disease (n = 4; 117.0 pg/mL; IQR, 90.3-232.4) compared
TABLE 2 Differences between
survivors and nonsurvivors among dogs
with leptospirosis with and without LPHS
Variable n Survivors n Nonsurvivors P value
Age (y) 27 5 (1-8) 4 8 (3.5-8.6) .26
Body weight (kg) 27 26 (16-34) 5 25 (10.4-28.9) .42
Thrombocytes (103/μL) 26 155 (126-269) 5 70 (29-79)& .007
Leucocyte count (103/μL) 26 13.3 (9.8-15.3) 5 19.5 (12.0-21.7) .1
Mature neutrophils (103/μL) 26 10.6 (8.0-12.5) 5 15.5 (10.4-17.7) .07
Band neutrophils (103/μL) 26 0.1 (0-0.3) 5 0.49 (0.32-0.75)& .02
Total protein (g/dL) 27 5.72 (5.19-6.41) 5 4.67 (3.67-5.17)& .01
Albumin (g/dL) 27 2.67 (2.31-2.94) 5 2.1 (1.66-2.51)& .02
Bilirubin (mg/dL) 27 0.20 (0.16-0.26) 5 3.7 (1.10-13.82)* .001
CRP (mg/L) 15 42 (32-126) 4 65 (48-107) .48
Abbreviations: CRP, C-reactive protein; LPHS, leptospiral pulmonary hemorrhage syndrome; n, number of
samples.
*P ≤ .05 after Bonferroni correction.
&P ≤ .05 Kruskal-Wallis Multiple Comparison Z-test.
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to dogs that survived to discharge (n = 18; 32.4 pg/mL; IQR, 21.2-
57.9; P = .004; Figure 2B).
Day 3 serum VEGF concentrations were below the limit of detec-
tion in the only 2 samples available from dogs with leptospirosis with-
out LPHS, while median day 3 concentrations were 20.5 ng/mL (IQR,
15-121; n = 5) in dogs with AKI and 58.1 ng/mL (IQR, 21-111.4;
n = 4) in dogs with LPHS. The difference between groups was not
statistically significant (P = .09).
3.5 | Serum Ang-2 concentrations
Median day 1 serum Ang-2 concentrations were significantly higher
in dogs with AKI-nL (n = 13; 8.5 ng/mL; IQR, 6.2-12.3), leptospiro-
sis (n = 9; 9.6 ng/mL; IQR, 6.9-19.3), and LPHS groups (n = 12;
8.0 ng/mL; IQR, 5.6-12.2) compared to healthy controls (n = 31;
5.4 ng/mL; IQR, 4.6-7.3; P < .001). There was no statistically signifi-
cant difference in Ang-2 serum concentrations between disease
groups (Figure 1C).
There was no significant difference in day 1 Ang-2 concentrations
among dogs with leptospirosis with or without LPHS between survi-
vors (n = 18; 9.5 ng/mL; IQR, 6.5-13.3) and nonsurvivors (n = 3;
8.7 ng/mL; IQR, 5.9-34.1; Figure 2C). The small number of day 3 sam-
ples precluded statistical analysis of this time point.
3.6 | Correlation analysis
Serum sICAM-1 and VEGF concentrations were moderately but sig-
nificantly positively correlated with segmented neutrophil count, bili-
rubin concentration and CRP, and negatively correlated with plasma
albumin. There was a significant moderate positive correlation of
sICAM-1 and VEGF. Both sICAM-1 and VEGF were weakly positively
correlated with Ang-2 (Table 3). Serum Ang-2 was not significantly
correlated with most markers of inflammation, except for a very weak
correlation with CRP.
3.7 | ROC analysis
Optimum cutoff values, sensitivities, specificities and AUC to discrimi-
nate healthy from diseased dogs (AKI-nL, leptospirosis, LPHS), dogs
with leptospirosis with and without LPHS from dogs with AKI-nL,
dogs with LPHS from dogs without LPHS and to predict a negative
outcome among dogs with leptospirosis with or without LPHS for
sICAM-1, VEGF, and Ang-2 are shown in Table 4.
All 3 markers discriminated between healthy and diseased dogs
with reasonable accuracy, although the sensitivity of serum Ang-2
was limited. Among dogs with leptospirosis, sICAM-1 was the only
1 of the 4 markers which was associated with the occurrence of
LPHS, albeit with low sensitivity (57%), but high specificity (100%).
In contrast to Ang-2, sICAM-1 and VEGF predicted a negative
outcome (death or euthanasia) with high accuracy.
F IGURE 1 A-C, Day 1 serum soluble intercellular adhesion
molecule (sICAM-1; A), vascular endothelial growth factor (VEGF; B),
and angiopoietin-2 serum concentrations (Ang-2; C) in healthy dogs
and dogs with acute kidney injury due to other etiologies (AKI-nL),
leptospirosis without pulmonary hemorrhage (Lepto), and dogs with
leptospiral pulmonary hemorrhage syndrome (LPHS). Median
sICAM-1, VEGF, and Ang-2 concentrations are significantly higher in
the 3 disease groups compared to healthy controls, but there is no
significant difference between disease groups. The central lines in the
boxes represent the median values, and the top and bottom of the
boxes represent the 75th and 25th percentiles, respectively
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4 | DISCUSSION
The results of this study show that concentrations of serum markers
of endothelial cell activation (sICAM-1) and dysfunction (VEGF and
Ang-2) are significantly increased in day 1 samples of dogs with lepto-
spirosis with or without LPHS compared to clinically healthy control
dogs. However, a significant elevation was also observed in dogs with
AKI due to other etiologies. These findings suggest that the 3 disease
groups have a similar degree of endothelial activation and dysfunction
upon admission and therefore do not support the hypothesis that
infection with Leptospira spp. leads to a specifically high degree of
endothelial activation and dysfunction as suggested in in vitro
models.9,10,30-32 Median day 3 concentrations of sICAM-1 and VEGF
suggested further activation or dysregulation in dogs with LPHS com-
pared to AKI-nL and leptospirosis without LPHS groups, but the avail-
able numbers of samples were too small to draw a more general
conclusion.
Endothelial activation, increased endothelial permeability, and
inflammation are closely interlinked. Increased concentration of endo-
thelial markers might therefore be a consequence of a systemic
inflammatory response to infection or uremic inflammation.9,10,30-32
In this cohort, soluble ICAM-1 and VEGF were positively correlated
with CRP and neutrophil count and negatively correlated with albu-
min, a negative acute phase protein. In contrast, Ang-2 was only
weakly correlated with CRP. Increases in sICAM-1 and VEGF are
therefore closely related to the systemic inflammatory response in
dogs with AKI (due to leptospirosis or other etiologies), while Ang-2
might be less inflammation driven in this setting.
Upon renal injury, renal endothelial cells and proximal tubular
epithelial cells produce pro-inflammatory cytokines and chemokines
leading to systemic inflammation.31 Cytokine profiles including IL-1a,
IL-1b, TGF-b and the enzyme 5-lipoxygenase in dogs with renal injury
due to leptospirosis are indistinguishable from those with AKI of non-
infectious causes.32 In addition, serum CRP concentrations are not
significantly different between dogs with leptospirosis-associated AKI
and AKI due to other causes. Together these findings suggest that
dogs with leptospirosis, LPHS, and AKI-nL have a similar degree of
systemic inflammation and likely inflammatory-associated endothelial
activation.
Soluble ICAM-1 and VEGF concentrations at admission were sig-
nificantly higher in nonsurvivors than survivors and increased serum
concentrations predicted a negative outcome with high accuracy. Fur-
thermore, increased sICAM-1 serum concentrations correctly
predicted LPHS in 72% of dogs with leptospirosis. Beyond a better
understanding of the pathogenic mechanisms of leptospirosis and
LPHS, sICAM-1 might therefore represent a useful biomarker to iden-
tify dogs at risk of LPHS.
In contrast, Ang-2 had no discriminatory power to predict the
occurrence of LPHS or death in dogs with leptospirosis. In dogs with
sepsis or SIRS, Ang-2 is significantly higher in nonsurviving compared
to surviving dogs and Ang-2 serum concentrations of >25.3 ng/mL are
highly predictive of death.27 The lack of association of Ang-2 serum
F IGURE 2 A-C, Day 1 serum soluble intercellular adhesion
molecule (sICAM-1; A), vascular endothelial growth factor (VEGF; B),
and angiopoietin-2 serum concentrations (Ang-2; C) in surviving and
nonsurviving dogs with leptospirosis with or without pulmonary
hemorrhage. Median sICAM-1 and VEGF serum concentrations are
significantly higher in nonsurvivors compared to survivors. The central
lines in the boxes represent the median values, and the top and
bottom of the boxes represent the 75th and 25th percentiles,
respectively
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concentrations with outcome in dogs with leptospirosis might be due
to particularities of the pathogenic mechanisms of leptospirosis-
associated sepsis. Leptospiral infection triggers an increase of pro-
inflammatory cytokines comparable to other Gram-negative infec-
tions.32,33 However, compared to other Gram-negative bacteria, lep-
tospiral lipopolysaccharide is of low endotoxicity and is recognized by
the TLR-2 rather than the TLR-4 receptor, suggesting different mecha-
nisms of cell immune response.34,35 Differences in the pathogenic
mechanism are likely also reflected by the fact that commonly used
outcome prediction severity scoring systems used in intensive care
settings, such as the sequential organ failure assessment score or the
Acute Physiology and Chronic Health Evaluation II (APACHE II) score
overestimate death from sepsis in humans with severe leptospirosis.36
Limitations of this study include the limited number of dogs per
study group, and the relative heterogenicity in the AKI-nL group. The
separation between leptospirosis without LPHS and leptospirosis with
LPHS groups was based on the presence of clinical signs and infil-
trates on thoracic radiographs and was not confirmed by
bronchoalveolar lavage, which could have led to misclassification of
individual dogs. Furthermore, only 10/31 dogs in the control group
TABLE 3 Correlation of day 1 serum soluble intercellular adhesion molecule-1 (sICAM-1), vascular endothelial growth factor (VEGF), and
Angiopoietin-2 (Ang-2) with markers of inflammation
Variable
sICAM-1 VEGF Ang-2
Spearman ρ P value Spearman ρ P value Spearman ρ P value
Leucocyte count 0.48 <.001 0.36 .01 0.18 .26
Mature neutrophils 0.51 <.001 0.44 .002 0.26 .09
Band neutrophils 0.38 .009 0.36 .01 0.18 .22
Albumin 0.52 .001 0.6 <.001 0.24 .11
Bilirubin 0.52 <.001 0.64 <.001 0.38 .01
CRP 0.65 <.001 0.7 <.001 0.38 .04
D1 Ang-2 0.26 .04 0.47 <.001 — —
D1 VEGF 0.68 <.001 — — .47 <.001
D1 sICAM-1 — — 0.68 <.001 0.26 .04
Abbreviation: CRP, C-reactive protein.
TABLE 4 Sensitivities, specificities, and areas under the curve (AUC) for optimum cutoff concentrations to predict disease (AKI due to other
causes, leptospirosis without or with LPHS) and a negative outcome in dogs with leptospirosis without LPHS or with leptospiral pulmonary
hemorrhage syndrome
Outcome AUC (95% CI) Cutoff Sensitivity (95% CI) Specificity (95% CI) Z-value (AUC > 0.5) P value
Healthy vs diseased (AKI-nL/Lepto/LPHS)
sICAM-1 (ng/mL) 0.86 (0.74-0.93) 25.1 0.87 (0.73-0.96) 0.81 (0.63-0.93) 8.0 .0
VEGF (pg/mL) 0.88 (0.77-0.93) 13.9 0.80 (0.64-0.91) 0.97 (0.83-1.0) 9.4 .0
Ang-2 (ng/mL) 0.81 (0.68-0.89) 8.3 0.53 (0.35-0.7) 0.90 (0.74-0.98) 5.8 .0
Leptospirosis vs AKI-nL
sICAM-1 (ng/mL) 0.61 (0.38-0.77) 43.5 0.7 (0.47-0.87) 0.63 (0.34-0.85) 1.1 .14
VEGF (pg/mL) 0.51 (0.3-0.67) 25.8 0.82 (0.6-0.95) 0.3 (0.13-0.59) 0.1 .47
Ang-2 (ng/mL) 0.55 (0.32-0.73) 5.2 0.95 (0.76-1.0) 0.23 (0.05-0.54) 0.5 .31
LPHS vs Lepto
sICAM-1 (ng/mL) 0.72 (0.43-0.88) 68.4 0.57 (0.29-0.82) 1.0 (0.66-1.0) 2.0 .02
VEGF (pg/mL) 0.62 (0.32-0.81) 49.6 0.57 (0.29-0.82) 0.75 (0.35-0.97) 1.0 .17
Ang-2 (ng/mL) 0.35 (0.09-0.57) — — — 1.2 .88
Death or euthanasia in dogs with Lepto or LPHS
sICAM-1 (ng/mL) 0.93 (0.71-0.99) 73.4 1.0 (0.4-1.0) 0.9 (0.67-1.0) 8.3 .0
VEGF (pg/mL) 0.97 (0.73-1.0) 87.1 1.0 (0.4-1.0) 0.9 (0.66-1.0) 14.0 .0
Ang-2 (ng/mL) 0.52 (0.06-0.84) 34.1 0.33 (0.01-0.91) 0.94 (0.73-1.0) 0.1 .47
Abbreviations: AKI, acute kidney injury; AKI-nL, acute kidney injury due to other etiologies; CI, confidence interval; Lepto, leptospirosis without leptospiral
pulmonary hemorrhage syndrome; LPHS, leptospiral pulmonary hemorrhage syndrome; sICAM-1, soluble intercellular adhesion molecule-1; VEGF, vascular
endothelial growth factor.
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had CBC and biochemistry panels performed to support their good
health and to be included in the correlation analysis of endothelial cell
activation or dysfunction markers with other blood markers of inflam-
mation such as neutrophilia, left shift, and CRP.
Finally, while the results of this study strongly suggest that dogs
with leptospirosis and AKI-nL have significantly higher sICAM-1 con-
centrations compared to healthy dogs, these results have to be
treated with caution, due to the high interassay variability observed
for the sICAM-1 ELISA.
5 | CONCLUSION
Serum concentration of markers of endothelial activation and dys-
function are increased in dogs with AKI due to leptospirosis and other
causes compared to healthy dogs. The correlations with other markers
of inflammation suggest that endothelial activation is related to sys-
temic inflammatory response to either infection or uremic inflamma-
tion. Among dogs with leptospirosis VEGF and ICAM-1 serum
concentrations predicted death with high accuracy. Soluble ICAM-1
was the only of the 4 markers which was associated with the occur-
rence of LPHS in this study sample, but this result has to be inter-
preted with caution as the canine sICAM-1 ELISA used had high
interassay variability.
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